Bloomberg -- Merck & Co.’s enlarged-prostate treatment Proscar failed to win the support of a U.S. advisory panel for use in preventing prostate cancer. Outside advisers to the Food and Drug Administration voted 17-0 with one abstention today that Proscar has an unfavorable balance of risks and benefits in healthy men at least 55 years old. Merck, based in Whitehouse Station, New Jersey, asked to add data from its studies in prostate cancer to the prescribing information for Proscar, approved in 1992.
